Literature DB >> 16008777

Electrodermal predictors of functional outcome and negative symptoms in schizophrenia.

Anne M Schell1, Michael E Dawson, Anthony Rissling, Joseph Ventura, Kenneth L Subotnik, Michael J Gitlin, Keith H Nuechterlein.   

Abstract

The ability of electrodermal variables to predict negative symptoms and functional outcome over a 1-year period in schizophrenia was investigated in 78 young, recent-onset outpatients. Patients were stabilized on standardized medication and largely free of psychotic symptoms. Higher levels of both tonic (skin conductance level, nonspecific skin conductance response rate) and phasic (number of skin conductance orienting responses) activity were associated with more negative symptoms and with a combination of poorer social and occupational outcome at 1-year follow-up. This pattern was seen in both male and female patients, and in older and younger patients. Results are interpreted as suggesting that high levels of arousal and overreactivity to the environment may interfere with efficient cognitive processing in schizophrenia, contributing to poor outcome, and that negative symptoms might partially serve as a means of coping with overarousal.

Entities:  

Mesh:

Year:  2005        PMID: 16008777     DOI: 10.1111/j.1469-8986.2005.00300.x

Source DB:  PubMed          Journal:  Psychophysiology        ISSN: 0048-5772            Impact factor:   4.016


  20 in total

1.  Empathy in electrodermal responsive and nonresponsive patients with schizophrenia.

Authors:  Satoru Ikezawa; Silvia Corbera; Jiacheng Liu; Bruce E Wexler
Journal:  Schizophr Res       Date:  2012-10-09       Impact factor: 4.939

2.  Assessment of Lifespan Functioning Attainment (ALFA) scale: A quantitative interview for self-reported current and functional decline in schizophrenia.

Authors:  Jamie Joseph; William S Kremen; Stephen J Glatt; Carol E Franz; Sharon D Chandler; Xiaohua Liu; Barbara K Johnson; Ming T Tsuang; Elizabeth W Twamley
Journal:  J Psychiatr Res       Date:  2015-04-11       Impact factor: 4.791

3.  The interaction of electrodermal activity and expressed emotion in predicting symptoms in recent-onset schizophrenia.

Authors:  Kenneth L Subotnik; Anne M Schell; Mark S Chilingar; Michael E Dawson; Joseph Ventura; Kimberle A Kelly; Gerhard S Hellemann; Keith H Nuechterlein
Journal:  Psychophysiology       Date:  2012-06-08       Impact factor: 4.016

4.  Effortful cognitive resource allocation and negative symptom severity in chronic schizophrenia.

Authors:  Eric Granholm; Steven P Verney; Dimitri Perivoliotis; Tamie Miura
Journal:  Schizophr Bull       Date:  2006-09-06       Impact factor: 9.306

Review 5.  Development of Autonomic Nervous System Assays as Point-of-Care Tests to Supplement Clinical Judgment in Risk Assessment for Suicidal Behavior: A Review.

Authors:  William V McCall; Peter B Rosenquist; Brian J Miller
Journal:  Curr Psychiatry Rep       Date:  2022-01-25       Impact factor: 5.285

6.  Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naive psychosis.

Authors:  Ripu D Jindal; Matcheri S Keshavan; Kevin Eklund; Angela Stevens; Debra M Montrose; Vikram K Yeragani
Journal:  Schizophr Res       Date:  2009-07-01       Impact factor: 4.939

7.  May salivary alpha-amylase level be a useful tool for assessment of the severity of schizophrenia and evaluation of therapy? A case report.

Authors:  Masa Ieda; Tsuyoshi Miyaoka; Kiminori Kawano; Rei Wake; Takuji Inagaki; Jun Horiguchi
Journal:  Case Rep Psychiatry       Date:  2012-09-30

8.  Physiological and behavioral differences in sensory processing: a comparison of children with autism spectrum disorder and sensory modulation disorder.

Authors:  Sarah A Schoen; Lucy J Miller; Barbara A Brett-Green; Darci M Nielsen
Journal:  Front Integr Neurosci       Date:  2009-11-03

Review 9.  Markers of vulnerability in schizophrenia.

Authors:  Maria Ladea; Dan Prelipceanu
Journal:  J Med Life       Date:  2009 Apr-Jun

10.  Initial Results of Tests Using GSR Biofeedback as a New Neurorehabilitation Technology Complementing Pharmacological Treatment of Patients with Schizophrenia.

Authors:  Renata Markiewicz; Beata Dobrowolska
Journal:  Biomed Res Int       Date:  2021-06-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.